Marleen Kok

Principal Investigator

The Netherlands Cancer Institute
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Clinicopathological features according to ER expression in the TONIC trial cohort Clinicopathological features of patients in the TONIC trial cohort, reported according to ER expression status (ER-low vs ER-0).

Year:

2025

Evolution of PD-L1 status from primary BC to relapse according to phenotypic evolution from primary BC to metastases. Sankey plots showing the evolution of PD-L1 status from primary breast cancer to relapse, according to phenotypic evolution (stable triple-negative breast cancer, from ER+/HER2- to ER-low, and from ER+/HER2- to triple-negative breast cancer).

Year:

2025

Most relevant findings from the signature comparisons (analysis of 770 genes) in ER-low and TNBC metastatic samples from the TONIC trial. Boxplots showing differential expression of ESR1 and selected immune-related signatures in ER-low and triple-negative metastatic samples from the TONIC trial.

Year:

2025

Multivariate analysis for overall survival and post relapse survival in the retrospective cohort in patients with ER+/HER2- primary BC. Multivariable Cox proportional hazards analyses for overall survival and post-relapse survival in the retrospective cohort of patients with primary ER+/HER2- breast cancer; hazard ratios (HRs) with 95% confidence intervals and p-values are reported.

Year:

2025

Purpose: The purpose of this study was to assess prognosis of estrogen receptor (ER)–low expression and its dynamics in HER2− metastatic breast cancer and to compare sensitivity to nivolumab between ER-low and triple-negative breast cancer (TNBC). Experimental Design: Two cohorts were analyzed: a multicenter cohort of 982 patients with HER2− metastatic breast cancer and one prospective cohort of 110 patients with ER Results: A total of 7.3% of retrospective cases had ER-low breast cancer, 15 of 110 of the TONIC trial. In the retrospective cohort, patients with ER-low breast cancer had significantly poorer OS ( P P = 0.230) compared with ER+/HER2− breast cancer and numerically longer OS ( P = 0.098) and significantly longer PRS ( P = 0.017) compared with TNBC. In the TONIC trial, patients with ER-low breast cancer, compared with TNBC, showed similar response to nivolumab (clinical benefit rate: 20.0% vs. 22.1%; P = 1), progression-free survival (median, 1.7 vs. 2.0 months; P = 0.5), and OS (median, 5.3 vs. 8.6 months; P = 0.3). Among patients with primary ER+/HER2− breast cancer ( n = 565), the conversion toward ER-low breast cancer or TNBC at metastasis conferred independent negative prognostic impact both for OS ( P = 0.002 and P = 0.001, respectively) and PRS ( P = 0.018 and P = 0.001, respectively). Conclusions: We provided evidence of the prognostic role of ER-low expression and its dynamics in patients with HER2− metastatic breast cancer. We offered insights into sensitivity to anti-PD1 in metastatic breast cancer, showing that patients with ER-low breast cancer have comparable likelihood of responding to nivolumab as those with TNBC.

Year:

2025

Distribution of PAM50 intrinsic subtypes across ER-low, TN and ER-low metastatic samples of patients with ER+/HER2- primary tumors. Donut plots showing the distribution of PAM50 intrinsic subtypes in metastatic samples from patients with ER+/HER2- primary breast cancer, according to phenotypic evolution (conversion to ER-low, conversion to triple-negative, or stable ER+/HER2-).

Year:

2025

Genes up-regulated or down-regulated in estrogen-receptor (ER)-low (ER 1-9%) vs ER-positive (>10%) by quantitative Significance Analysis of Microarrays (SAM) analysis List of genes significantly up- or down-regulated in tumors that switched from ER+/HER2– to ER-low (1–9%) compared with tumors maintaining a stable ER-positive (≥10%) phenotype, as identified by quantitative Significance Analysis of Microarrays (SAM).

Year:

2025

Representativeness of Study Participants. Representativeness of study participants in the context of advanced breast cancer, with information on sex, age, race/ethnicity, geography, and overall comparability to the general patient population.

Year:

2025

Triple-negative breast cancer (TNBC) is a subtype with limited treatment options and poor outcomes, particularly in the metastatic setting. Although immunotherapy has shown efficacy in early-stage disease, its benefit remains suboptimal in women with locally advanced and metastatic TNBC. Here, we identify the splicing factor PTBP1 as a tumor-intrinsic regulator of immune evasion in metastatic TNBC. By integrating clinical, single-cell, and bulk transcriptomic data with multiplex immunohistochemistry, CRISPR-Cas9 genome editing, and functional assays, we show that PTBP1 impairs antigen presentation, promotes T cell dysfunction, and is associated with worse outcomes, independent of tumor-infiltrating lymphocyte levels. Furthermore, CRISPR-mediated silencing of PTBP1 restores HLA expression and reactivates antigen presentation pathways in TNBC. PTBP1 expression is elevated in metastatic compared to primary TNBC tumors and correlates with immune dysfunction signatures. Consistently, in the phase II TONIC clinical trial, metastatic TNBC patients with PTBP1-high tumors had poor response and shorter survival following PD-1 blockade, and PTBP1 expression showed a predictive performance comparable to PD-L1 and TILs in this cohort. These findings position PTBP1 as a tumor-intrinsic regulator of immune evasion and a potential biomarker to inform immunotherapy strategies in metastatic TNBC.

Year:

2025

Triple-negative breast cancer (TNBC) has an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. Human leukocyte antigen-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCR) from naïve repertoires. Following gene introduction into T cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize noncognate epitopes from alternative source proteins. Notably, this TCR-mediated killing of three-dimensional (3D) tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T cells as a treatment for the vast majority of patients with TNBC. Significance: Metastatic TNBC has a dismal prognosis. This study discovers Ropporin-1 as a target for T-cell therapy for most patients. The selected TCR is highly specific and sensitive in advanced models, and preclinical testing shows that the T-cell product expressing this TCR, manufactured according to good manufacturing practice, has favorable safety and potency.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (19)

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Jeroen Demmers

Associate Professor | Director of the Proteomics Core Facility

Erasmus MC

NETHERLANDS
View details

Lodewyk Wessels

Professor

Delft University of Technology

NETHERLANDS
View details

Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

John W. M. Martens

-

NETHERLANDS
View details

Carla M.L. van Herpen

Radboud University Medical Center

NETHERLANDS
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Gaia Griguolo

University of Padua

ITALY
View details

Angelo Paolo Dei Tos

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Ann Hoeben

Maastricht University Medical Centre

NETHERLANDS
View details

Henk Verheul

Professor of Medical Oncology

Erasmus MC

NETHERLANDS
View details

Sonja Buschow

Assistant professor

Erasmus University Rotterdam

NETHERLANDS
View details

Matteo Fassan

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Maria Vittoria Dieci

Assistant professor (Ricercatore tempo determinato tipo B)

University of Padova

ITALY
View details

Federico Piacentini

PROF. ASSOCIATO

University of Modena and Reggio Emilia

ITALY
View details

Hans Gelderblom

Prof.dr

Leiden University Medical Center

NETHERLANDS
View details

erik danen

Leiden University

NETHERLANDS
View details

Michal Bassani-Sternberg

University of Lausanne

SWITZERLAND
View details

Maggie L. DiNome

Medical Director, Breast Cancer Services Wake County

Duke University School of Medicine

UNITED STATES
View details